NO20042737L - Peroksisomproliferatoraktiverte receptoragonister - Google Patents

Peroksisomproliferatoraktiverte receptoragonister

Info

Publication number
NO20042737L
NO20042737L NO20042737A NO20042737A NO20042737L NO 20042737 L NO20042737 L NO 20042737L NO 20042737 A NO20042737 A NO 20042737A NO 20042737 A NO20042737 A NO 20042737A NO 20042737 L NO20042737 L NO 20042737L
Authority
NO
Norway
Prior art keywords
receptor agonists
activated receptor
peroxisome proliferator
proliferator activated
peroxisome
Prior art date
Application number
NO20042737A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Craig Thompson
Jr Leonard Larry Winneroski
Yanping Xu
Nathan Bryan Mantlo
Richard Duane Johnston
Tracey Ann Gibson
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20042737L publication Critical patent/NO20042737L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20042737A 2001-11-30 2004-06-29 Peroksisomproliferatoraktiverte receptoragonister NO20042737L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33445301P 2001-11-30 2001-11-30
PCT/US2002/036128 WO2003048130A2 (en) 2001-11-30 2002-11-26 Peroxisome proliferator activated receptor agonists

Publications (1)

Publication Number Publication Date
NO20042737L true NO20042737L (no) 2004-08-17

Family

ID=23307275

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042737A NO20042737L (no) 2001-11-30 2004-06-29 Peroksisomproliferatoraktiverte receptoragonister

Country Status (19)

Country Link
US (1) US7544812B2 (enExample)
EP (1) EP1453811A2 (enExample)
JP (1) JP2005517643A (enExample)
KR (1) KR20050044606A (enExample)
CN (1) CN1582279A (enExample)
AU (1) AU2002356927A1 (enExample)
BR (1) BR0214437A (enExample)
CA (1) CA2468846A1 (enExample)
CO (1) CO5640129A2 (enExample)
EA (1) EA007163B1 (enExample)
HR (1) HRP20040469A2 (enExample)
HU (1) HUP0402486A3 (enExample)
IL (1) IL161578A0 (enExample)
MX (1) MXPA04005123A (enExample)
NO (1) NO20042737L (enExample)
NZ (1) NZ532909A (enExample)
PL (1) PL370515A1 (enExample)
WO (1) WO2003048130A2 (enExample)
ZA (1) ZA200404173B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
DE10351859A1 (de) * 2003-11-06 2005-06-09 Beiersdorf Ag Emulsionen mit zwei Verdickungsmitteln
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
WO2006036512A2 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
CA2655574A1 (en) 2006-06-20 2007-12-27 Wyeth Imidazole kv1.5 potassium channel inhibitors
FR2903984B1 (fr) * 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CN101875636B (zh) * 2010-05-18 2012-01-04 浙江大学 咪唑啉-2,4-二酮类衍生物及制备方法和用途
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CN115894379B (zh) * 2022-01-20 2025-06-27 哈尔滨三联药业股份有限公司 海因类化合物及其医药用途
CN114835655A (zh) * 2022-04-14 2022-08-02 河南师范大学 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法
LU605402B1 (en) * 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452041A (en) * 1965-05-19 1969-06-24 American Home Prod Hydantoin compounds and methods of preparation
HU183046B (en) 1976-06-03 1984-04-28 Wellcome Found Process for producing hydanthoine derivatives
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS59159163A (ja) * 1983-03-01 1984-09-08 Fuji Photo Film Co Ltd ハロゲン化銀カラ−感光材料
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
PT966447E (pt) 1997-03-03 2003-07-31 Boehringer Ingelheim Pharma Moleculas pequenas uteis no tratamento de doencas inflamatorias
WO2001016120A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Also Published As

Publication number Publication date
CA2468846A1 (en) 2003-06-12
US7544812B2 (en) 2009-06-09
WO2003048130A2 (en) 2003-06-12
HRP20040469A2 (en) 2004-10-31
EP1453811A2 (en) 2004-09-08
HUP0402486A2 (hu) 2005-03-29
JP2005517643A (ja) 2005-06-16
CN1582279A (zh) 2005-02-16
HUP0402486A3 (en) 2007-05-02
ZA200404173B (en) 2005-08-23
NZ532909A (en) 2006-08-31
PL370515A1 (en) 2005-05-30
BR0214437A (pt) 2004-10-13
MXPA04005123A (es) 2005-02-17
WO2003048130A3 (en) 2003-11-20
EA200400748A1 (ru) 2004-12-30
IL161578A0 (en) 2004-09-27
US20050020652A1 (en) 2005-01-27
AU2002356927A1 (en) 2003-06-17
EA007163B1 (ru) 2006-08-25
CO5640129A2 (es) 2006-05-31
KR20050044606A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE386026T1 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
IL161578A0 (en) Peroxisome proliferator activated receptor agonists
NL1018939A1 (nl) Maandverband.
NO20025115L (no) Muskarin agonister
IS7040A (is) 5-HT viðtakabindlar og notkun þeirra
ATE388937T1 (de) Agonisten des cannabinoidrezeptors
DE60237381D1 (de) Reinigungsgerät
EE200300244A (et) 3-aroüülindooli derivaadid ja nende kasutamine CB2-retseptorite agonistidena
DE60115555D1 (de) Funduskamera
BR8102729Y1 (pt) dispositivo portÁtil para higienizaÇço dental.
DE60106800D1 (de) Funduskamera
DK1465923T3 (da) Corticotroprinafgivende faktor 2-receptoragonister
DE60200863D1 (de) Doppeltelezentrisches Objektiv
ATE291900T1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
AU2002347985A1 (en) Peroxisome proliferator activated receptor alpha agonists
DE60142038D1 (de) Aktivatoren des peroxisome proliferator-activated rezeptors
NO20013978D0 (no) Dopamin D1 reseptor agonist forbindelser
HK1071563A (en) Peroxisome proliferator activated receptor agonists
ATE491683T1 (de) Muskarine agonisten
ITAR20010016A0 (it) Dispositivo sollevatore-abbassatore per bagni
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
FI20020878A7 (fi) Kaapimislaite
ES1048063Y (es) Dispositivo de retraccion perfeccionado.
NO992250D0 (no) Fingerb°lltannb°rste